Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 257-077-0 | CAS number: 51240-95-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vitro / ex vivo
- Adequacy of study:
- supporting study
- Reliability:
- other: Expert statement is attached.
- Rationale for reliability incl. deficiencies:
- other: No studies are available on the toxicokinetics, metabolism and distribution of dihexadecyl peroxodicarbonate. Predictions were made based on physical-chemical properties and information from tox. studies.
Data source
Materials and methods
Test material
Reference
- Name:
- Unnamed
- Type:
- Constituent
Results and discussion
Applicant's summary and conclusion
- Executive summary:
Basic Toxicokinetics for 1,1,3,3-tetramethylbutyl peroxyneodecanoate (CAS# 51240-95-0)
In order to fulfill the requirements for submission of a REACH dossier according to Annex IX of REACH Regulation (EC) No.1907/2006 (for substances >100 tones/year) and in absence of data on the toxicokinetics and dermal absorption, an assessment of toxicological behaviour is required.No studies are available on the toxicokinetics, metabolism and distribution of 1,1,3,3-tetramethylbutyl peroxyneodecanoate.
1,1,3,3-tetramethylbutyl peroxyneodecanoate is unstable with a hydrolysis half lifeless than 24 hours at 15°C (OECD111).The pure peroxide is not commercially available and always used in closed systems. Due to its instability, a phlegmatizer is added. Therefore the commercial product is always a mixture of peroxide and phlegmatizer.
Multiple breakdown products were identified (Datta, 2012). The breakdown products were not quantified. 1,1,3,3-tetramethylbutyl peroxyneodecanoate is converted to TMBH hydroperoxide (CAS#5809-08-5) which is broken down to neopentyl alcohol (CAS#75-84-3).Other breakdown products are 2,2,4-trimethylpentanol-2 (CAS# 123-44-4) and acetone (CAS# 67-64-1).
Below are some physical chemical properties of 1,1,3,3-tetramethylbutyl peroxyneodecanoate and a common phlegmatizer, isododecane (CAS# 93685-81-5)
Endpoint
1,1,3,3-tetramethylbutyl peroxyneodecanoate
Isododecane
Mixture
MW
300.48
170.34
-
WS
33.6 µg/L
Insoluble (Supplier SDS); 4.86 ug/L (Disseminated Dossier); 43.57 ug/L (EPIWEB)
-
Log Pow
>6.5 (6.9 extrapolated)
6.96 (QSAR cal from disseminated dossier); 6.01 (EPIWEB)
-
VP
0.0001 -0.01Pa 25°C(calculated)
180 Pa (measured)
<0.24 Pa at 25°C(measured)
Skin irritation
Cannot assess the irritation potential of the peroxide alone due to stability issues.
Repeated exposure can defat skin and lead to irritation (supplier SDS)
Irritant Cat 2
NOTE: All measurements are based on experimental work with a phlegmatizer/peroxide mixture and/or calculation. The pure peroxide is highly unstable and will completely decompose. 1,1,3,3-Tetramethyl- butyl peroxyneodecanoates 70% in isododecane is classified as a peroxidetype D. Flammability is an intrinsic hazard in this class.
The Self-Accelerating Decomposition Temperature (SADT) of the substances is 15°C (reference SADT: CLP regulations 2.15.2.3 and UN Recommendations on the Transport of Dangerous Goods, Manual of Tests and Criteria, 5th revised edition, sub-sections 28.1, 28.2, 28.3 and Table 28.3.)
The available physico-chemical and toxicological information of the substance has been evaluated and used to assess the toxicological behaviour. The results of this analysis will address the question on how the chemical will react in the body.
The ECHA “Guidance on information requirements and chemical safety assessment Chapter R.7c: Endpoint specific guidance May 2008” document provides guidance, which physico-chemical properties commonly determine oral, inhalatory and dermal absorption, distribution, metabolism and elimination of substances(Link:http://echa.europa.eu/documents/10162/13632/information_requirements_r7c_en.pdf)
Dermal Absorption
Based on the log Pow of 6.9, the peroxide is expected to stay partitioned in the phlegmatizer. Based on the log Pow of 6.96, vapor pressure and water solubility, the phlegmatizer is not expected to penetrate the skin to a significant degree. Therefore, the peroxide would not be expected to be significantly absorbed either. The substance is mildly irritating to skin and increased absorption due to damaged skin is therefore not very likely.
If absorbed however, the peroxide would quickly undergo thermal decomposition at body temperature to multiple breakdown products.
Inhalation Absorption
The measured vapor pressure of the peroxide isododecane mixture was<0.24 Pa at 25°Cand of the peroxide 0.0001 -0.01Pa°C. Based on the low vapor pressure and pattern of use, inhalation is not expected to be a major route of exposure. If inhalation of the peroxide does occur, as stated above it will rapidly decompose to multiple breakdown products.
Oral Absorption
A 28-day oral gavage study, of the peroxide (70%) in phlegmatizer, in rats, resulted in effects on the kidneys of males (alpha 2μglobulin), livers of males and females (increase liver weights, diffuse hepatocellular hypertrophy) and thyroid follicular hypertrophy and minimally-slightly increased extramedullary hemopoiesis at 30 mg/kg/day. The liver effects were considered adaptive and the alpha 2μglobulin is specific to the male rat. The effects on the thyroid are a secondary effect due to increased metabolism of T3/T4 and the observations in the spleen are caused by an increased demand.
In a 90-day oral gavage study reported in the REACH disseminated dossier, the phlegmatizer was administered to rats at 500, 2500 and 5000 mg/kg/day. The same liver effects were reported at 2500 and 5000 mg/kg/day. The same kidney effects were reported in all dose groups.
While it is not possible to establish the causative agent of the effects noted in the 28-day study with the product, (i.e. the solvent or peroxide), the peroxide is expected to quickly decompose at body temperature to multiple breakdown products.
Conclusion
While toxicokinetic data is not available on 1,1,3,3-tetramethylbutyl peroxyneodecanoate, if absorbed, it is expected to be rapidly converted to multiple breakdown products. 1,1,3,3-tetramethylbutyl peroxyneodecanoate is not expected to bioaccumulate.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Route: .live2